Key Takeaways: Wiley - Andrew ACE Suite Test Event - LLM

Executive Summary

Dr. Kiran Patil presented research showing that non-antibiotic human drugs and environmental pollutants, especially fungicides and PFAS, can significantly inhibit commensal gut bacteria, often via shared resistance mechanisms like efflux pumps that also drive antimicrobial resistance. His lab’s systematic single bug–single chemical screens reveal that roughly a quarter of human-targeted drugs negatively impact gut microbes, drug effects can outweigh diet in shaping microbiomes, and bacteria both biotransform and bioaccumulate drugs, demonstrated mechanistically with duloxetine binding metabolic enzymes and altering bacterial physiology. Extending to pollutants, chemical structure–based machine learning predicts microbial impact, and genetic screens link transport regulation to cross-resistance between pesticides and antibiotics. Notably, certain gut bacteria extensively sequester PFAS, accelerating fecal clearance in mice, suggesting microbiome-mediated strategies to mitigate exposure and informing safe-by-design chemicals and probiotic interventions.

Speakers

Tessa Grefenstette, Associate Director, Search & Evolution
Jason Moore, Director of Engineering

Key Takeaways

1. Medications Disrupt Microbiomes: Non-antibiotic human drugs frequently disrupt the gut microbiome, with ~25% of human-targeted medications inhibiting at least one commensal strain in vitro and medication usage explaining more microbiome variance than diet in some cohorts.

2. Cross-Resistance Drives AMR: Shared resistance mechanisms such as efflux pumps link responses to antibiotics, human drugs, and pollutants, meaning exposure to non-antibiotic compounds can select for antimicrobial resistance, especially under polypharmacy.

3. Microbial Drug Sequestration: Gut microbes both transform and sequester drugs, with strain-specific bioaccumulation altering drug exposure and effects (e.g., duloxetine binding bacterial metabolic enzymes and changing host-relevant responses in C. elegans).

4. Predictive Safe-by-Design: Many environmental chemicals, notably fungicides and PFAS, exert strong antibacterial effects or accumulate in gut bacteria; machine learning on chemical structure now predicts bacterial impact, enabling “safe-by-design” considerations.

5. Microbiome-Modulated PFAS Clearance: Certain gut bacteria sequester long-chain PFAS at high levels, accelerating fecal clearance in mouse models, suggesting microbiome composition can influence toxicokinetics and may be harnessed to mitigate pollutant burden.

Key Quote

“Chemical classes are arbitrary. Bacteria don’t care; shared mechanisms like efflux pumps mean non‑antibiotic drugs and environmental pollutants can impact gut microbes and even promote antibiotic resistance.”

Related Content

Explore Related Content.

Webinar

Watch Full Webinar here.

FAQs: Wiley - Andrew ACE Suite Test Event - LLM

Frequently Asked Questions

Wiley - Andrew ACE Suite Test Event - LLM

Microbiome Basics and Individual Variation

Why does the gut microbiome matter for health and chemical exposures?

The gut microbiome functions like an organ with vast metabolic capacity, its genetic diversity is 50–100 times greater than ours. It contributes to immune training, nutrient processing, and drug and chemical metabolism. Because microbiome composition varies widely between individuals (often only ~10% similarity), microbiome-driven differences can strongly influence how people respond to medications and environmental pollutants.

What determines a person’s gut microbiome composition?

Diet and lifestyle are key drivers (e.g., fiber intake, alcohol, smoking), but medication use—beyond antibiotics—can be a dominant factor in some cohorts. Early-life microbiomes are highly dynamic; after adolescence they tend to stabilize, though travel, illness, and medications can cause shifts.

Medications and the Microbiome

Do non-antibiotic drugs affect gut bacteria?

Yes. In lab screens, about 25% of human-targeted (non-antibiotic) drugs inhibited at least one common gut bacterium. Classes include antipsychotics, NSAIDs, and proton pump inhibitors. This helps explain gastrointestinal side effects (e.g., diarrhea) seen with some non-antibiotic drugs and aligns with cohort data where medication use correlates with microbiome shifts.

Can drug–microbiome interactions confound disease–microbiome studies?

Yes. Reanalyses of type 2 diabetes cohorts showed that microbiome differences originally attributed to disease were largely due to metformin use. Accounting for medication exposure is essential to avoid misattributing drug effects to disease.

Can non-antibiotic drugs promote antibiotic resistance in gut bacteria?

Potentially. Some resistance mechanisms are shared across chemical classes. For example, efflux pumps that expel antibiotics can also handle non-antibiotic drugs. Cohort data link polypharmacy to higher antimicrobial resistance gene abundance, suggesting non-antibiotic exposure may select for cross-resistance.

Do gut bacteria also change drugs?

Yes. Gut microbes can biotransform drugs (chemically modify them) or bioaccumulate them (take them up without chemical change). Classic examples include sulfasalazine activation by microbial enzymes. Newer work shows extensive, previously unrecognized biotransformation and bioaccumulation across many drugs.

Why is duloxetine highlighted as a case study?

Duloxetine, an antidepressant, can be taken up by some bacterial strains, bind numerous metabolic enzymes, and alter bacterial physiology, demonstrated with proteome-wide assays. Strain-level differences in drug accumulation can change the effective dose experienced by the host, as shown in C. elegans, helping explain variability in response and GI side effects.

Communities, Emergent Effects, and Mechanisms

Do single-species drug effects hold in communities?

Often, yes, around 60% of single bug–single drug effects carry over to mixed communities. However, community interactions can produce emergent protection (a drug becomes less toxic due to other species) or sensitization (more toxic in a community), influenced by drug biotransformation, bioaccumulation, and metabolite cross-feeding.

What common bacterial mechanisms underlie responses to diverse chemicals?

Transport processes are central. Efflux pumps (e.g., involving TolC in E. coli) reduce intracellular drug levels, conferring tolerance to both antibiotics and non-antibiotics. Forward-genetic screens in other species (e.g., Parabacteroides) similarly identify transport regulation as a shared resistance determinant across pesticides and antibiotics.

Environmental Pollutants and Gut Bacteria

Do pesticides and industrial chemicals harm gut bacteria?

Many do. Large-scale screens show numerous pesticides and industrial chemicals inhibit commensal gut bacteria. Notably, some fungicides exhibit broad antibacterial activity, underscoring limited target specificity. Sensitivity to pharmaceuticals and pollutants correlates across strains, indicating shared vulnerabilities and mechanisms.

Can we predict which chemicals will disrupt gut bacteria?

Yes, to a useful extent. Using a dataset of >2,000 compounds (drugs, pesticides, antibiotics), machine-learning models based on chemical structure can predict antibacterial effects on gut strains. This supports a ‘safe by design’ approach for future chemicals.

Are PFAS (‘forever chemicals’) handled by gut bacteria?

Certain gut bacteria can strongly bioaccumulate long-chain PFAS (e.g., PFNA, PFOA), sequestering them in intracellular aggregates without immediate harm to the bacteria. Imaging and genetic evidence point to active transport and efflux control. In mice colonized with PFAS-accumulating human gut strains, fecal PFAS excretion increases, suggesting the microbiome can influence PFAS toxicokinetics.

Can toothpaste fluoride become PFAS in the body?

No. Forming PFAS requires creating strong carbon–fluorine bonds under industrial conditions. Normal physiological environments do not synthesize PFAS from everyday fluoride sources like toothpaste.

Is there effective microbial breakdown of long-chain PFAS in the gut?

Current evidence suggests efficient microbial biotransformation is mainly limited to very short-chain PFAS; long-chain PFAS that accumulate in humans are far more recalcitrant. Research is ongoing to find better degradation strategies.

Practical Implications and Mitigation

How might these findings impact drug development and environmental policy?

Drug pipelines and chemical risk assessments should account for microbiome interactions, both toxicity to commensals and microbial metabolism/accumulation that alters exposure. Structure-based prediction and mechanistic assays enable earlier screening, while considering transport-mediated cross-resistance can inform stewardship and regulation.

Are there ways to reduce negative impacts of pollutants on the gut microbiome?

While clinical guidance should come from healthcare professionals, general measures include: using effective water filtration (e.g., reverse osmosis) to lower contaminant exposure; thorough washing of produce to reduce pesticide residues; and maintaining a fiber-rich diet, which epidemiological data associate with reduced accumulation of some pollutants. Future microbiome-based strategies (e.g., probiotics that sequester PFAS) are under development.

Blog: When Non‑Antibiotics Act Like Antibiotics: Gut Microbes, Drug Efficacy, and Resistance Risk

Human-made chemicals act on the host and the gut microbiome. That dual exposure shifts how we think about efficacy, safety, and resistance. Microbiome composition varies far more than the human genome and directly influences immunity, nutrition, and xenobiotic processing. Many common drugs reshape microbial communities as strongly as diet. For toxicology and drug development, every compound should be assessed as engaging both human cells and microbial ecosystems, with consequences for therapeutic performance and risk.

Microbial Networks Rewire Chemical Effects In mixed communities, xenobiotics encounter sequestration, export, and metabolism that can either protect or sensitize the host: - Protection: neighboring microbes can bind, pump out, or transform compounds, lowering potency observed in monoculture. - Sensitization: cross-feeding and metabolite shifts can convert seemingly benign agents into harmful exposures under community conditions. Bioaccumulation and biotransformation drive both outcomes. The same transport and detox mechanisms that undermine antibiotics can also alter the activity of fungicides, food-contact chemicals, and other pollutants. Prediction and risk management require a host–microbe lens rather than legacy categories.

Non‑Antibiotic Drugs, Commensals, and Resistance Two directions matter: 1) Drugs perturb microbes - High-throughput screens show ~25% of human-targeted drugs inhibit at least one common gut commensal. Therapeutic classes extend far beyond antibiotics. - Sensitivity patterns correlate across antibiotics and non-antibiotics, pointing to shared resistance mechanisms (for example, efflux). - Real-world polypharmacy cohorts link medication exposure to large fractions of microbiome variance and increases in antimicrobial resistance gene (ARG) abundance. Implication: non-antibiotic medications contribute to antimicrobial resistance selection pressure and belong in environmental and clinical resistance frameworks. 2) Microbes modify drugs - Biotransformation is widespread, beyond classic pro-drug cases. Unexpected bioaccumulation is common: bacteria take up drugs unchanged, bind them to proteins, and rewire metabolism. - Proteome-level thermal shifts appear in bioaccumulating strains exposed to certain antidepressants, absent in non-accumulators—implicating transport differences as a primary driver. - These strain-level differences affect host pharmacokinetics and pharmacodynamics by buffering, delaying, or amplifying exposure and reshaping community structure.

Translational impact: - In vivo, bioaccumulating bacteria can blunt antidepressant efficacy; non-accumulating strains do not. - Selectivity scoped only to human targets misses microbiome off-targets that alter efficacy and adverse events.

Operational recommendations: - Treat the microbiome as a dynamic exposure modifier and mode-of-action contributor. - Expand measurement beyond human tissues: profile colon drug concentrations, microbial strain composition, resistance determinants, and metabolites. - Design studies that integrate drug metadata, microbiome sequencing, and metabolomics to strengthen causal inference in safety and efficacy assessments.

Microbiome-Centric Chemical Risk and Prediction Non-antibiotic chemicals, notably some fungicides, display strong antibacterial activity against gut strains. Structure–effect maps across thousands of molecules show: - Blurred boundaries between pharmaceuticals and pollutants: structural clusters often contain both, and sensitivity profiles correlate across classes. - Cross-resistance: strains resistant to a human drug often resist an environmental pollutant, consistent with shared transport and detox pathways (efflux pumps). - Predictive modeling opportunity: harmonized, multi-species, multi-dose assays can train models that infer microbial impact from chemical features with high accuracy for pre-market triage and post-market surveillance.

Mechanistic underpinnings: - Genetic screens identify transport regulators as cross-category resistance modules. Loss of a single regulator in a Bacteroides relative can confer resistance to both a common antiparasitic residue and ciprofloxacin, linking pesticide tolerance and antibiotic resistance. - These transport-driven mechanisms shape community resilience under realistic, chronic low-dose mixtures.

Action for regulators and developers: - Prioritize compound classes that show persistent antibacterial activity or overlap with clinically relevant resistance pathways. - Combine broad screening libraries with mechanistic follow-up to parse transport, efflux, and metabolic contributions.

Persistent Chemicals and Microbial Handling Microbes also change toxicokinetics of persistent pollutants: - Certain gut strains strongly bioaccumulate long-chain PFAS via active, regulated transport and intracellular clustering, contradicting the assumption of membrane-only partitioning. - In vivo, colonization with PFAS-accumulating human strains increases fecal elimination and accelerates clearance. Implication: microbiome composition influences internal PFAS burden and half-life, reframing interindividual variability and creating intervention paths.

Translational strategies: - Probiotics or synbiotics designed to sequester specific chemicals in the gut, potentially combined with diet to support colonization and binding. - Microbiome-informed water treatment and exposure reduction strategies.

Pragmatic Actions for Chemical Risk Management - Integrate microbial-impact screens: add gut commensal panels to assessment pipelines and adopt shared data standards to train structure-based classifiers that flag gut-disruptive activity before scale-up. - Run mechanism-led follow-ups: use transport inhibitors, efflux profiling, genome-wide screens, and metabolomics to distinguish protection from sensitization and anticipate mixture effects. - Pilot microbiome-informed mitigation: - Exposure control: point-of-use reverse osmosis for PFAS, and tighter specs for high-risk fungicides and degradants. - Microbial sequestration: evaluate targeted probiotic or synbiotic approaches to reduce systemic exposure for persistent chemicals. - Consumer guidance: simple, low-risk steps like rigorous produce washing to lower pesticide residues and higher-fiber diets that can aid binding and excretion.

Clinical and Regulatory Integration - Incorporate non-antibiotic medication exposure into resistance surveillance and environmental risk frameworks. - Preclinical screens for commensal toxicity, biotransformation, and bioaccumulation, with specific attention to efflux-linked resistance selection. - For marketed drugs, track GI adverse events through a microbiome lens and mitigate via formulation changes, dosing adjustments, or microbiome-stabilizing co-therapies. - Stratify patients by microbiome features to reduce variability in efficacy and safety; incorporate colon-level drug concentration and microbial function into pharmacokinetic modeling.

Chemicals act on human cells and gut microbes. Non-antibiotic drugs and pollutants exert antibacterial pressure through shared transport and resistance networks, while microbes can sequester or transform xenobiotics, altering exposure and outcomes. Standardized microbial assays, predictive models, and genetic mapping—paired with safe-by-design chemistry and microbiome-guided mitigation, offer a practical framework to de-risk products and improve therapeutic performance. Evaluate chemicals by functional impact, not legacy labels, and treat the microbiome as both exposure modifier and intervention target to deliver more precise risk estimates and better health outcomes.